Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q1

2160.TEDINET S100TFYV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥5.9bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥26.0bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥4.2bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥2.3bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥398m2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥1.8bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥12.6bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥65m2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥1.5bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.1bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥3m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥1.3bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥9.5bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥342m2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥65.6bnat 2024-03-31Cons.Assets IFRS
Total assets¥62.4bnat 2023-12-31Cons.Assets IFRS
Total assets¥34.1bnat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥27.8bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥26.3bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥37.8bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥36.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥19.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥34.6bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥33.8bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.2bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥20.3bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.6bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥350m2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥710m2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.8bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥6.8bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.2bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥88m2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥10.7bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥52m2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥29.172024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥169.52023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-0.062023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥282024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥165.562023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-0.062023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio52.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio54.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.2%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue2024-01-01 → 2024-03-31¥1.3bn
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue external2024-01-01 → 2024-03-31¥1.3bn
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentsegment profit2024-01-01 → 2024-03-31¥539m
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue2024-01-01 → 2024-03-31¥4.6bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue external2024-01-01 → 2024-03-31¥4.6bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentsegment profit2024-01-01 → 2024-03-31¥1.7bn
—segment totalrevenue2024-01-01 → 2024-03-31¥5.9bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥5.9bn
—segment totalsegment profit2024-01-01 → 2024-03-31¥2.3bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥23m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥23m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-03-31¥623m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-03-31¥600m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥23m
jpcrp040300-q1r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-03-31¥248m
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-03-31¥3.6bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-03-31¥3.6bn
jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-03-31¥149m
—segment totalrevenue2023-01-01 → 2023-03-31¥4.2bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥4.2bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥23m
—segment totalsegment profit2023-01-01 → 2023-03-31¥398m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 599
ItemContextValueUnit
Proceeds from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration151226000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-51798000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-76950000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-51798000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-87618000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration129156000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration947994000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-452460000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-1290963000JPY
Cash and cash equivalents IFRSPrior2YearInstant11049310000JPY
Cash and cash equivalents IFRSPrior1YearInstant21633028000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant10596849000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant20342064000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember3606336000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember599799000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember4206135000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration4206135000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember22896000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember22896000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-22896000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember3606336000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember622695000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember4229032000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-22896000JPY
Revenue IFRSPrior1YTDDuration4206135000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember149207000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember248390000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember397598000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSPrior1YTDDuration397598000JPY
Finance income IFRSPrior1YTDDuration49329000JPY
Finance costs IFRSPrior1YTDDuration239599000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-272262000JPY
Profit loss before tax IFRSPrior1YTDDuration-64934000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember4628680000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember1319888000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember5948569000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration5948569000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember4628680000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember1319888000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember5948569000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass